Angiotensin (ANG)-converting enzyme (ACE2) is an entry receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19). ACE2 also contributes to a deviation of the lung renin–angiotensin system (RAS) towards its counter-regulatory axis, thus transforming harmful ANG II to protective ANG (1–7). Based on this purported ACE2 double function, it has been put forward that the benefit from ACE2 upregulation with renin–angiotensin–aldosterone system inhibitors (RAASi) counterbalances COVID-19 risks due to counter-regulatory RAS axis amplification. In this manuscript we discuss the relationship between ACE2 expression and function in the lungs and other organs and COVID-19 severity. Recent data suggested that the involvement of ACE2 in the lung counter-regulatory RAS axis is limited. In this setting, an augmentation of ACE2 expression and/or a dissociation of ACE2 from the ANG (1–7)/Mas pathways that leaves unopposed the ACE2 function, the SARS-CoV-2 entry receptor, predisposes to more severe disease and it appears to often occur in the relevant risk factors. Further, the effect of RAASi on ACE2 expression and on COVID-19 severity and the overall clinical implications are discussed.
【저자키워드】 COVID-19, ACE2, renin–angiotensin system, 【초록키워드】 coronavirus disease, SARS-CoV-2, coronavirus, Risk factors, COVID-19 severity, lung, risk, RAS, amplification, pathway, inhibitor, ACE2 expression, Protective, angiotensin, RAASi, severe disease, acute respiratory syndrome, enzyme, entry receptor, upregulation, manuscript, deviation, recent, benefit, appear, contribute, occur, suggested, cause, ANG, clinical implication, other organ, the SARS-CoV-2, 【제목키워드】 axis, System,